HRP20192230T1 - Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita - Google Patents
Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita Download PDFInfo
- Publication number
- HRP20192230T1 HRP20192230T1 HRP20192230TT HRP20192230T HRP20192230T1 HR P20192230 T1 HRP20192230 T1 HR P20192230T1 HR P20192230T T HRP20192230T T HR P20192230TT HR P20192230 T HRP20192230 T HR P20192230T HR P20192230 T1 HRP20192230 T1 HR P20192230T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacological agent
- tat
- peptide
- intended
- mast cell
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 18
- 210000003630 histaminocyte Anatomy 0.000 title claims 11
- 239000003112 inhibitor Substances 0.000 title claims 9
- 239000003795 chemical substances by application Substances 0.000 title claims 2
- 238000011260 co-administration Methods 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 claims 19
- 229960004305 lodoxamide Drugs 0.000 claims 7
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical group OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 3
- XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical group CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 230000028709 inflammatory response Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 108010046423 Tat-NR2B9c Proteins 0.000 claims 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 2
- 229960002071 bepotastine Drugs 0.000 claims 2
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 claims 2
- 229960003633 chlorzoxazone Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims 2
- 229960003449 epinastine Drugs 0.000 claims 2
- 229940039009 isoproterenol Drugs 0.000 claims 2
- 229960004114 olopatadine Drugs 0.000 claims 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims 2
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 claims 2
- 229960004439 pemirolast Drugs 0.000 claims 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 2
- 229960005330 pimecrolimus Drugs 0.000 claims 2
- 229960005414 pirbuterol Drugs 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims 2
- 229960005342 tranilast Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 230000001960 triggered effect Effects 0.000 claims 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 1
- 102000047174 Disks Large Homolog 4 Human genes 0.000 claims 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims 1
- 101710195187 Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 claims 1
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000012660 pharmacological inhibitor Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u liječenju ili profilaksi bolesti, naznačeno time što se farmakološko sredstvo primijenjuje s inhibitorom degranuliranja mastocita radi inhibiranja upalnog odgovora kojeg može potaknuti peptid TAT; a inhibitor degranuliranja mastocita je lodoksamid, tranilast, bepotastin, klorzoksazon, epinastin, izoproterenol, olopatadin, pemirolast, pimekrolimus ili pirbuterol.
2. Farmakološko sredstvo namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se inhibitor degranuliranja mastocita suformulira s farmakološkim sredstvom, inhibitor degranuliranja mastocita je lodoksamid, a farmakološko sredstvo je Tat-NR2B9c.
3. Farmakološko sredstvo spojeno s peptidom TAT primijenjuje s inhibitorom degranuliranja mastocita, koji inhibira upalni odgovor kojeg može potaknuti peptid TAT, naznačeno time što je namijenjeno upotrebi u liječenju ili profilaksi inzulta, epilepsije, hipoksije, traumatske ozljede CNS koja nije povezana s inzultom, Alzheimerove bolesti, Parkinsonove bolesti, ili pacijent nad kojim se provodi kirurški zahvat koji utječe ili može utjecati na opskrbu krvnim žilama ili uklanjanje krvi iz mozga, gdje sredstvo inhibira međudjelovanja između PSD-95 i NMDAR2B, te je peptid koji sadrži SEQ ID NO:38 na C-kraju, a inhibitor degranuliranja mastocita je lodoksamid, tranilast, bepotastin, klorzoksazon, epinastin, izoproterenol, olopatadin, pemirolast, pimekrolimus ili pirbuterol.
4. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što je farmakološko sredstvo Tat-NR2B9c.
5. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što peptid TAT ima aminokiselinski slijed koji sadrži RKKRRQRRR (SEQ ID NO:51), GRKKRRQRRR (SEQ ID NO:1), YGRKKRRQRRR (SEQ ID NO:2), FGRKKRRQRRR (SEQ ID NO:3) ili GRKKRRQRRRPQ (SEQ ID NO:4) ili RRRQRRKKRGY (aminokiseline 1-11 u SEQ ID NO:70).
6. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se inhibitor degranuliranja mastocita primijenjuje perifernim putem.
7. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se inhibitor degranuliranja mastocita primijenjuje u intervalu od 30 minuta prije 15 nakon primjene farmakološkog sredstva.
8. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što je namijenjeno primjeni na subjektu koji boluje od epizode bolesti, te gdje se farmakološko sredstvo i inhibitor degranuliranja mastocita primijenjuje jednom tijekom epizode bolesti.
9. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što se suformulaciju primijenjuje intravenski.
10. Farmakološko sredstvo spojeno s peptidom TAT namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se farmakološko sredstvo također primijenjuje uz antihistaminik.
11. Komplet, naznačen time što sadrži farmakološko sredstvo spojeno s peptidom TAT, te lodoksamid.
12. Lodoksamid, naznačen time što je namijenjen upotrebi u inhibiranju upalnog odgovora kojeg može uzrokovati degranuliranje mastocita kao odgovor kojeg može potaknuti farmakološko sredstvo spojeno s peptidom TAT.
13. Suformulacija, naznačena time što sadrži lodoksamid i peptid s aminokiselinskim slijedom SEQ ID NO:6 (YGRKKRRQRRRKLSSIESDV), te vodu.
14. Suformulacija pripravka u skladu s patentnim zahtjevom 13, naznačena time što dodatno sadrži natrijev klorid u koncentraciji od 50-200 mM, te gdje je koncentracija lodoksamida 0,5-1 mg/ml, a koncentracija peptida je 5-20 mg/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18594309P | 2009-06-10 | 2009-06-10 | |
| EP10786870.5A EP2440231B1 (en) | 2009-06-10 | 2010-06-10 | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
| PCT/US2010/038226 WO2010144742A2 (en) | 2009-06-10 | 2010-06-10 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192230T1 true HRP20192230T1 (hr) | 2020-03-20 |
Family
ID=43309471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192230TT HRP20192230T1 (hr) | 2009-06-10 | 2019-12-12 | Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8933013B2 (hr) |
| EP (2) | EP2440231B1 (hr) |
| JP (5) | JP5886192B2 (hr) |
| AU (1) | AU2010259986B2 (hr) |
| CA (2) | CA3018494C (hr) |
| CY (1) | CY1122584T1 (hr) |
| DK (1) | DK2440231T3 (hr) |
| ES (1) | ES2765281T3 (hr) |
| HR (1) | HRP20192230T1 (hr) |
| HU (1) | HUE046640T2 (hr) |
| LT (1) | LT2440231T (hr) |
| PL (1) | PL2440231T3 (hr) |
| PT (1) | PT2440231T (hr) |
| SI (1) | SI2440231T1 (hr) |
| WO (1) | WO2010144742A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| WO2010004003A2 (en) * | 2008-07-09 | 2010-01-14 | University Of Copenhagen | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| HUE046640T2 (hu) | 2009-06-10 | 2020-03-30 | Nono Inc | TAT-internalizáló peptidhez kapcsolt hatóanyag együttes beadása egy hízósejt degranuláció-inhibitorral |
| PT3354657T (pt) | 2009-09-22 | 2022-05-06 | Medicago Inc | Método de preparação de proteínas derivadas de plantas |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| HUE058238T2 (hu) | 2011-06-24 | 2022-07-28 | Nono Inc | Ischaemia kombinációs terápiája |
| PL2925338T3 (pl) * | 2012-11-28 | 2019-11-29 | Nono Inc | Liofilizowana formulacja TAT-NR2B9C |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| WO2016172219A1 (en) * | 2015-04-24 | 2016-10-27 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation |
| KR102403089B1 (ko) * | 2017-07-05 | 2022-06-02 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도 |
| JP7450534B2 (ja) | 2017-10-19 | 2024-03-15 | 帝人ファーマ株式会社 | ベンズイミダゾール誘導体及びその用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| AU2354700A (en) | 1998-12-11 | 2000-06-26 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US7595297B2 (en) | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| EP1210121A2 (en) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| US6887687B2 (en) | 2001-07-30 | 2005-05-03 | Immunex Corporation | Nucleic acids encoding human ataxin-1-like polypeptide IMX97018 |
| WO2004045535A2 (en) * | 2002-11-14 | 2004-06-03 | Arbor Vita Corporation | Molecular interactions in neurons |
| WO2004071531A1 (en) | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| WO2005037317A2 (en) * | 2003-10-17 | 2005-04-28 | Cornell Research Foundation, Inc. | Mast cell-derived renin |
| US20050256065A1 (en) * | 2004-01-26 | 2005-11-17 | Permasight | Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents |
| US7151084B2 (en) | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| KR101384572B1 (ko) | 2005-12-30 | 2014-04-24 | 아버 비타 코포레이션 | Ｐｄｚ 상호작용의 소형 분자 억제제 |
| WO2008008348A2 (en) * | 2006-07-11 | 2008-01-17 | Arbor Vita Corporation | Method and compositions for treating stroke with fever |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| WO2008109010A1 (en) * | 2007-03-02 | 2008-09-12 | Arbor Vita Corporation | Treating stroke and other diseases without inhibiting n-type calcium channels |
| WO2009006611A1 (en) | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| CA2694046C (en) | 2007-07-26 | 2023-09-12 | Revance Therapeutics, Inc. | Cationic peptides and compositions thereof |
| ES2328776B1 (es) | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| WO2010004003A2 (en) | 2008-07-09 | 2010-01-14 | University Of Copenhagen | Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction |
| HUE046640T2 (hu) * | 2009-06-10 | 2020-03-30 | Nono Inc | TAT-internalizáló peptidhez kapcsolt hatóanyag együttes beadása egy hízósejt degranuláció-inhibitorral |
-
2010
- 2010-06-10 HU HUE10786870A patent/HUE046640T2/hu unknown
- 2010-06-10 LT LTEP10786870.5T patent/LT2440231T/lt unknown
- 2010-06-10 EP EP10786870.5A patent/EP2440231B1/en active Active
- 2010-06-10 PT PT107868705T patent/PT2440231T/pt unknown
- 2010-06-10 DK DK10786870.5T patent/DK2440231T3/da active
- 2010-06-10 AU AU2010259986A patent/AU2010259986B2/en active Active
- 2010-06-10 PL PL10786870T patent/PL2440231T3/pl unknown
- 2010-06-10 US US13/377,519 patent/US8933013B2/en active Active
- 2010-06-10 SI SI201031965T patent/SI2440231T1/sl unknown
- 2010-06-10 EP EP19210675.5A patent/EP3682895A1/en not_active Withdrawn
- 2010-06-10 CA CA3018494A patent/CA3018494C/en active Active
- 2010-06-10 WO PCT/US2010/038226 patent/WO2010144742A2/en active Application Filing
- 2010-06-10 JP JP2012515161A patent/JP5886192B2/ja active Active
- 2010-06-10 CA CA2765171A patent/CA2765171C/en active Active
- 2010-06-10 ES ES10786870T patent/ES2765281T3/es active Active
-
2014
- 2014-12-29 US US14/585,028 patent/US9433685B2/en active Active
-
2015
- 2015-07-03 JP JP2015134712A patent/JP6238934B2/ja active Active
-
2016
- 2016-08-24 US US15/245,693 patent/US10046060B2/en active Active
-
2017
- 2017-09-19 JP JP2017179192A patent/JP6775478B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-12 US US16/034,235 patent/US20190038760A1/en not_active Abandoned
-
2019
- 2019-12-12 HR HRP20192230TT patent/HRP20192230T1/hr unknown
- 2019-12-23 CY CY20191101350T patent/CY1122584T1/el unknown
-
2020
- 2020-04-17 JP JP2020074428A patent/JP7209364B2/ja active Active
-
2022
- 2022-10-25 JP JP2022170797A patent/JP2023017813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192230T1 (hr) | Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita | |
| ES2523858T3 (es) | Fragmentos de VIP y composiciones de los mismos | |
| ES2369216T3 (es) | Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético. | |
| ES2523659T3 (es) | Composiciones y procedimientos para el tratamiento de enfermedades cardiovasculares | |
| ES2879550T3 (es) | Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares. | |
| JP2012530060A5 (hr) | ||
| CA2829101C (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| BR122020011001B1 (pt) | Peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos | |
| JP2009500045A5 (hr) | ||
| WO2011047097A3 (en) | Inhibition of trem receptor signaling with peptide variants | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| BRPI0914504B1 (pt) | uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv | |
| IL273169B2 (en) | A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases | |
| JP7071287B2 (ja) | 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 | |
| JP2012524112A5 (hr) | ||
| ES2924728T3 (es) | Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas | |
| CN103687593A (zh) | 组织蛋白酶k抑制用于治疗和/或预防肺动脉高压和/或心力衰竭的用途 | |
| Gheorghiade et al. | Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output | |
| Sharif-Alhoseini et al. | Underlying causes of paresthesia | |
| CN111032055A (zh) | 使用胰高血糖素样肽2的下尿路上皮的治疗 | |
| JP5477794B2 (ja) | エンドキニンｃ／ｄ由来のペプチド | |
| JP2014512369A5 (hr) | ||
| CA3088576A1 (en) | Composition for treating a patient suffering from ulcerative colitis, and use of the composition as a drug | |
| JP2008156312A (ja) | サブスタンスｐに対するペプチド由来のアンタゴニストの開発 | |
| CN103463007A (zh) | Racemosins A在制备治疗鼻炎药物中的应用 |